Literature DB >> 34302744

Combined glucocorticoid resistance and hyperlactatemia contributes to lethal shock in sepsis.

Jolien Vandewalle1, Steven Timmermans1, Ville Paakinaho2, Lies Vancraeynest3, Liza Dewyse4, Tineke Vanderhaeghen1, Charlotte Wallaeys1, Lise Van Wyngene1, Kelly Van Looveren1, Louise Nuyttens1, Melanie Eggermont1, Sylviane Dewaele1, Tiago R Velho5, Luis F Moita5, Sebastian Weis6, Christoph Sponholz7, Leo A van Grunsven4, Mieke Dewerchin8, Peter Carmeliet9, Karolien De Bosscher10, Johan Van de Voorde3, Jorma J Palvimo2, Claude Libert11.   

Abstract

Sepsis is a potentially lethal syndrome resulting from a maladaptive response to infection. Upon infection, glucocorticoids are produced as a part of the compensatory response to tolerate sepsis. This tolerance is, however, mitigated in sepsis due to a quickly induced glucocorticoid resistance at the level of the glucocorticoid receptor. Here, we show that defects in the glucocorticoid receptor signaling pathway aggravate sepsis pathophysiology by lowering lactate clearance and sensitizing mice to lactate-induced toxicity. The latter is exerted via an uncontrolled production of vascular endothelial growth factor, resulting in vascular leakage and collapse with severe hypotension, organ damage, and death, all being typical features of a lethal form of sepsis. In conclusion, sepsis leads to glucocorticoid receptor failure and hyperlactatemia, which collectively leads to a lethal vascular collapse.
Copyright © 2021 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  glucocorticoid resistance; hyperlactatemia; metabolism; sepsis; shock

Mesh:

Substances:

Year:  2021        PMID: 34302744     DOI: 10.1016/j.cmet.2021.07.002

Source DB:  PubMed          Journal:  Cell Metab        ISSN: 1550-4131            Impact factor:   27.287


  7 in total

1.  Glucocorticoid resistance and hyperlactatemia: A tag team to worsen sepsis.

Authors:  Monowar Aziz; Ping Wang
Journal:  Cell Metab       Date:  2021-09-07       Impact factor: 31.373

Review 2.  Neuroimmune Regulation in Sepsis-Associated Encephalopathy: The Interaction Between the Brain and Peripheral Immunity.

Authors:  Yu-Xiao Liu; Yang Yu; Jing-Peng Liu; Wen-Jia Liu; Yang Cao; Run-Min Yan; Yong-Ming Yao
Journal:  Front Neurol       Date:  2022-06-27       Impact factor: 4.086

3.  Reprogramming of glucocorticoid receptor function by hypoxia.

Authors:  Tineke Vanderhaeghen; Steven Timmermans; Deepika Watts; Ville Paakinaho; Melanie Eggermont; Jolien Vandewalle; Charlotte Wallaeys; Lise Van Wyngene; Kelly Van Looveren; Louise Nuyttens; Sylviane Dewaele; Joke Vanden Berghe; Kelly Lemeire; Joey De Backer; Laura Dirkx; Wim Vanden Berghe; Guy Caljon; Bart Ghesquière; Karolien De Bosscher; Ben Wielockx; Jorma J Palvimo; Rudi Beyaert; Claude Libert
Journal:  EMBO Rep       Date:  2021-10-26       Impact factor: 8.807

Review 4.  Dimerization of the Glucocorticoid Receptor and Its Importance in (Patho)physiology: A Primer.

Authors:  Steven Timmermans; Jolien Vandewalle; Claude Libert
Journal:  Cells       Date:  2022-02-15       Impact factor: 6.600

Review 5.  Extracellular Vesicles, New Players in Sepsis and Acute Respiratory Distress Syndrome.

Authors:  Wenqiang Jing; Huijuan Wang; Liying Zhan; Wei Yan
Journal:  Front Cell Infect Microbiol       Date:  2022-04-07       Impact factor: 6.073

6.  Cigarette smoke exposure reduces hemorrhagic shock induced circulatory dysfunction in mice with attenuated glucocorticoid receptor function.

Authors:  Martin Wepler; Jonathan M Preuss; Cornelia Tilp; Martina Keck; Jochen Blender; Ulrich Wachter; Tamara Merz; Josef Vogt; Sandra Kress; Michael Gröger; Andrea Hoffmann; Marina Fink; Enrico Calzia; Ute Burret; Peter Radermacher; Jan P Tuckermann; Sabine Vettorazzi
Journal:  Front Immunol       Date:  2022-09-12       Impact factor: 8.786

Review 7.  Glucocorticoids and COVID-19.

Authors:  Stefano Bruscoli; Pier Giorgio Puzzovio; Maria Zaimi; Katerina Tiligada; Francesca Levi-Schaffer; Carlo Riccardi
Journal:  Pharmacol Res       Date:  2022-10-12       Impact factor: 10.334

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.